Stock Yards Bank & Trust Co. Cuts Position in Edwards Lifesciences Co. (NYSE:EW)

Stock Yards Bank & Trust Co. trimmed its position in Edwards Lifesciences Co. (NYSE:EW) by 16.9% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 3,390 shares of the medical research company’s stock after selling 687 shares during the quarter. Stock Yards Bank & Trust Co.’s holdings in Edwards Lifesciences were worth $258,000 at the end of the most recent quarter.

A number of other large investors also recently modified their holdings of the company. Martin Capital Advisors LLP raised its holdings in shares of Edwards Lifesciences by 0.5% during the 4th quarter. Martin Capital Advisors LLP now owns 25,490 shares of the medical research company’s stock valued at $1,944,000 after buying an additional 128 shares during the period. Legacy Wealth Asset Management LLC raised its holdings in shares of Edwards Lifesciences by 0.8% during the 4th quarter. Legacy Wealth Asset Management LLC now owns 16,958 shares of the medical research company’s stock valued at $1,293,000 after buying an additional 134 shares during the period. DMC Group LLC raised its holdings in shares of Edwards Lifesciences by 4.5% during the 4th quarter. DMC Group LLC now owns 3,561 shares of the medical research company’s stock valued at $272,000 after buying an additional 154 shares during the period. Granite Harbor Advisors Inc. raised its holdings in shares of Edwards Lifesciences by 4.2% during the 3rd quarter. Granite Harbor Advisors Inc. now owns 3,832 shares of the medical research company’s stock valued at $265,000 after buying an additional 155 shares during the period. Finally, Stableford Capital II LLC increased its holdings in Edwards Lifesciences by 2.7% during the 4th quarter. Stableford Capital II LLC now owns 5,980 shares of the medical research company’s stock worth $449,000 after purchasing an additional 155 shares during the last quarter. 79.46% of the stock is currently owned by hedge funds and other institutional investors.

Edwards Lifesciences Trading Up 1.0 %

NYSE:EW opened at $88.62 on Thursday. Edwards Lifesciences Co. has a 12-month low of $60.57 and a 12-month high of $96.12. The firm has a market capitalization of $53.34 billion, a P/E ratio of 38.53, a P/E/G ratio of 4.35 and a beta of 1.05. The company has a debt-to-equity ratio of 0.09, a current ratio of 3.38 and a quick ratio of 2.40. The business has a 50 day simple moving average of $90.23 and a 200 day simple moving average of $78.69.

Edwards Lifesciences (NYSE:EW) last released its quarterly earnings data on Tuesday, February 6th. The medical research company reported $0.64 earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of $0.64. Edwards Lifesciences had a return on equity of 23.56% and a net margin of 23.35%. The business had revenue of $1.53 billion during the quarter, compared to analyst estimates of $1.50 billion. During the same quarter in the previous year, the firm posted $0.64 EPS. The business’s revenue for the quarter was up 13.3% compared to the same quarter last year. Equities research analysts predict that Edwards Lifesciences Co. will post 2.76 EPS for the current year.

Insiders Place Their Bets

In other Edwards Lifesciences news, CFO Scott B. Ullem sold 7,255 shares of the business’s stock in a transaction on Thursday, February 1st. The stock was sold at an average price of $78.29, for a total transaction of $567,993.95. Following the completion of the transaction, the chief financial officer now owns 19,248 shares in the company, valued at approximately $1,506,925.92. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. In other Edwards Lifesciences news, CFO Scott B. Ullem sold 7,255 shares of the business’s stock in a transaction on Thursday, February 1st. The stock was sold at an average price of $78.29, for a total transaction of $567,993.95. Following the completion of the transaction, the chief financial officer now owns 19,248 shares in the company, valued at approximately $1,506,925.92. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, VP Jean-Luc M. Lemercier sold 14,400 shares of the business’s stock in a transaction on Monday, April 8th. The stock was sold at an average price of $92.32, for a total value of $1,329,408.00. Following the transaction, the vice president now owns 173,849 shares of the company’s stock, valued at approximately $16,049,739.68. The disclosure for this sale can be found here. In the last quarter, insiders sold 194,004 shares of company stock worth $17,166,254. 1.29% of the stock is owned by company insiders.

Analysts Set New Price Targets

Several research firms have issued reports on EW. StockNews.com downgraded Edwards Lifesciences from a “buy” rating to a “hold” rating in a report on Wednesday, March 20th. Mizuho lifted their price objective on Edwards Lifesciences from $95.00 to $105.00 and gave the stock a “buy” rating in a report on Thursday, April 11th. Oppenheimer lifted their price objective on Edwards Lifesciences from $93.00 to $100.00 and gave the stock an “outperform” rating in a report on Monday, March 18th. Evercore ISI lifted their price objective on Edwards Lifesciences from $86.00 to $92.00 and gave the stock an “in-line” rating in a report on Thursday, April 4th. Finally, Citigroup lifted their price objective on Edwards Lifesciences from $90.00 to $98.00 and gave the stock a “neutral” rating in a report on Wednesday, April 3rd. One investment analyst has rated the stock with a sell rating, seven have issued a hold rating and ten have assigned a buy rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $91.73.

Edwards Lifesciences Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.